GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that its innovative Inogen One G4 portable oxygen concentrator is now allowed for use onboard commercial aircraft and the start of the domestic business-to-business sales channel launch. The launch of the Inogen One G4 in the domestic business-to-business sales channel will consist of a phased approach that is expected to take place throughout the third quarter.
The ultra-portable Inogen One G4, first released to the market on May 31, 2016, is the smallest and lightest oxygen concentrator that the Company has ever produced. Effective today, supplemental oxygen therapy patients are permitted to travel with the Inogen One G4 onboard commercial aircraft. At only 2.8 pounds, the Inogen One G4 is small and light-weight, allowing it to seamlessly fit into the lifestyles of active oxygen therapy patients, both on the ground and during air travel.
“The ability for the Inogen One G4 to be used during air travel will allow our oxygen users to reclaim their independence by traveling as they see fit with a portable oxygen concentrator weighing only 2.8 pounds,” said Raymond Huggenberger, Inogen’s CEO. “The Inogen One G4 is a single solution device meaning that it is capable of 24 hours a day, 7 days a week use at home, away, and now during commercial air travel.”
On May 24, 2016, the Department of Transportation and the FAA published a final rule concerning the acceptance criteria for portable oxygen concentrators used onboard aircraft. The final rule replaces the current product-by-product approval process and allows commercial aircraft passengers to use a portable oxygen concentrator onboard if the portable concentrator satisfies certain acceptance criteria and the product has a label indicating conformance with these criteria. The Inogen One G4 satisfies the criteria and the final rule implementation date is today, August 22, 2016. Oxygen users are still encouraged to contact their preferred airline in advance of their travel date to discuss any airline-specific requirements.
Today the Company also announced that this month it has initiated the launch of the Inogen One G4 in the domestic business-to-business sales channel. The launch of the product in this sales channel follows the product introduction to the Company’s direct-to-consumer sales channel on May 31, 2016 and is part of the Company’s planned and controlled rollout process. This process is expected to continue with future domestic and international business-to-business channel launches, pending receipt of any required regulatory approvals.
“The continual product innovations that we have demonstrated as well as the ability to use the Inogen One G4 during air travel are direct benefits to the supplemental oxygen therapy user and directly align with our mission to increase the freedom and independence of oxygen therapy patients around the world,” said Mr. Huggenberger. “In addition to these benefits, the start of the launch of the Inogen One G4 into the business-to-business channel will broaden awareness and increase accessibility of our life changing products, allowing even more patients to reclaim their freedom and independence.”
Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning Inogen’s expectations for market acceptance and broadened awareness of its Inogen One G4, Inogen’s belief that the Inogen One G4 can change and improve the lives of patients and allow them to reclaim their freedom and independence, and the expected timing and distribution channels for the ongoing rollout of the Inogen One G4. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks relating to market acceptance of Inogen’s products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations in customer operations; unanticipated increases in costs or expenses; risks associated with international operations, including risks associated with obtaining regulatory approval in foreign jurisdictions; and intellectual property risks if Inogen is unable to secure and maintain patent or other intellectual property protection for the intellectual property used in its products. Information on these and additional risks, uncertainties, and other information affecting Inogen's business and operating results are contained in Inogen's Annual Report on Form 10-K for the year ended December 31, 2015 and in Inogen's subsequent reports filed with the Securities and Exchange Commission, including Inogen's Quarterly Report on Form 10-Q for the period ended June 30, 2016. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.
Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
For more information, please visit www.inogen.com.